Progen Co., Ltd.
π°π·South Korea
Phase II Study of PG-102(MG12) Compared with Placebo in Obesity and Type 2 Diabetes
Phase 2
Recruiting
- Conditions
- Type 2 Diabetes Mellitus (T2DM)Obesity Type 2 Diabetes Mellitus
- Interventions
- Other: Placebo
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- ProGen. Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT06712615
- Locations
- π°π·
Kangbuk Samsung Hospital, Samsung Medical Center, Seoul, Korea, Republic of
π°π·KOREA University Anam Hospital, Seoul, Korea, Republic of
π°π·KOREA University Asan Hospital, Seoul, Korea, Republic of
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants.
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- ProGen. Co., Ltd.
- Target Recruit Count
- 102
- Registration Number
- NCT06309667
- Locations
- π°π·
Catholic University Seoul St.Mary Hospital,, Seocho, Seoul, Korea, Republic of
Β© Copyright 2025. All Rights Reserved by MedPath